NEW YORK, Feb. 04, 2019 (GLOBE NEWSWIRE) -- In
new independent research reports released early this morning,
Market Source Research released its latest key findings for all
current investors, traders, and shareholders of T-Mobile US, Inc.
(TMUS), Noble Corporation (NE), Akebia Therapeutics, Inc. (AKBA), Vornado Realty Trust (VNO), Bio-Rad Laboratories, Inc. (BIO), and Standex International Corporation
(SXI), including updated fundamental
summaries, consolidated fiscal reporting, and fully-qualified
certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available to readers at the links below.
TMUS DOWNLOAD: http://MarketSourceResearch.com/register/?so=TMUS
NE DOWNLOAD: http://MarketSourceResearch.com/register/?so=NE
AKBA DOWNLOAD: http://MarketSourceResearch.com/register/?so=AKBA
VNO DOWNLOAD: http://MarketSourceResearch.com/register/?so=VNO
BIO DOWNLOAD: http://MarketSourceResearch.com/register/?so=BIO
SXI DOWNLOAD: http://MarketSourceResearch.com/register/?so=SXI
(You may have to copy and paste the link into your browser and hit the [ENTER] key)
The new research reports from Market Source Research, available for free download at the links above, examine T-Mobile US, Inc. (TMUS), Noble Corporation (NE), Akebia Therapeutics, Inc. (AKBA), Vornado Realty Trust (VNO), Bio-Rad Laboratories, Inc. (BIO), and Standex International Corporation (SXI) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.
-----------------------------------------
Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed January 31st, 2019. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.
-----------------------------------------
T-MOBILE US, INC. (TMUS) REPORT OVERVIEW
T-Mobile US's Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, T-Mobile US reported revenue of $10,839.00MM vs $10,019.00MM (up 8.18%) and analysts estimated basic earnings per share $0.94 vs $0.65 (up 44.62%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, T-Mobile US reported revenue of $40,604.00MM vs $37,490.00MM (up 8.31%) and analysts estimated basic earnings per share $5.39 vs $1.71 (up 215.20%). Analysts expect earnings to be released on February 14th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was $0.48. The estimated EPS forecast for the next fiscal year is $3.99 and is expected to report on February 14th, 2019.
To read the full T-Mobile US, Inc. (TMUS) report, download it here: http://MarketSourceResearch.com/register/?so=TMUS
-----------------------------------------
NOBLE CORPORATION (NE) REPORT OVERVIEW
Noble's Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, Noble reported revenue of $279.41MM vs $266.21MM (up 4.96%) and analysts estimated basic earnings per share -$0.33 vs -$0.40. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Noble reported revenue of $1,236.92MM vs $2,302.07MM (down 46.27%) and analysts estimated basic earnings per share -$2.11 vs -$3.82. Analysts expect earnings to be released on February 20th, 2019. The report will be for the fiscal period ending December 31st, 2018. Reported EPS for the same quarter last year was -$0.29. The estimated EPS forecast for the next fiscal year is -$1.63 and is expected to report on February 20th, 2019.
To read the full Noble Corporation (NE) report, download it here: http://MarketSourceResearch.com/register/?so=NE
-----------------------------------------
AKEBIA THERAPEUTICS, INC. (AKBA) REPORT OVERVIEW
Akebia Therapeutics' Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, Akebia Therapeutics reported revenue of $53.17MM vs $41.28MM (up 28.79%) and analysts estimated basic earnings per share -$0.46 vs -$0.49. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Akebia Therapeutics reported revenue of $177.98MM vs $1.54MM (up 11,495.05%) and analysts estimated basic earnings per share -$1.77 vs -$3.60. Analysts expect earnings to be released on March 11th, 2019. The report will be for the fiscal period ending December 31st, 2018. Reported EPS for the same quarter last year was $0.25. The estimated EPS forecast for the next fiscal year is -$1.50 and is expected to report on March 11th, 2019.
To read the full Akebia Therapeutics, Inc. (AKBA) report, download it here: http://MarketSourceResearch.com/register/?so=AKBA
-----------------------------------------
VORNADO REALTY TRUST (VNO) REPORT OVERVIEW
Vornado Realty Trust's Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, Vornado Realty Trust reported revenue of $542.05MM vs $528.76MM (up 2.51%) and basic earnings per share $1.00 vs -$0.15. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Vornado Realty Trust reported revenue of $2,084.13MM vs $2,003.74MM (up 4.01%) and analysts estimated basic earnings per share $0.85 vs $4.36 (down 80.50%). Analysts expect earnings to be released on February 11th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was $0.98. The estimated EPS forecast for the next fiscal year is $3.99 and is expected to report on February 11th, 2019.
To read the full Vornado Realty Trust (VNO) report, download it here: http://MarketSourceResearch.com/register/?so=VNO
-----------------------------------------
BIO-RAD LABORATORIES, INC. (BIO) REPORT OVERVIEW
Bio-Rad Laboratories' Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, Bio-Rad Laboratories reported revenue of $545.14MM vs $534.14MM (up 2.06%) and analysts estimated basic earnings per share $9.02 vs $0.74 (up 1,118.92%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Bio-Rad Laboratories reported revenue of $2,160.15MM vs $2,068.17MM (up 4.45%) and analysts estimated basic earnings per share $4.12 vs $0.88 (up 368.18%). Analysts expect earnings to be released on February 26th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was $1.50. The estimated EPS forecast for the next fiscal year is $6.78 and is expected to report on February 26th, 2019.
To read the full Bio-Rad Laboratories, Inc. (BIO) report, download it here: http://MarketSourceResearch.com/register/?so=BIO
-----------------------------------------
STANDEX INTERNATIONAL CORPORATION (SXI) REPORT OVERVIEW
Standex International's Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, Standex International reported revenue of $193.08MM vs $189.14MM (up 2.08%) and analysts estimated basic earnings per share $1.25 vs $1.10 (up 13.64%). For the twelve months ended June 30th, 2018 vs June 30th, 2017, Standex International reported revenue of $868.38MM vs $755.26MM (up 14.98%) and analysts estimated basic earnings per share $2.88 vs $3.68 (down 21.74%). Analysts expect earnings to be released on May 7th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $1.11. The estimated EPS forecast for the next fiscal year is $6.50 and is expected to report on August 27th, 2019.
To read the full Standex International Corporation (SXI) report, download it here: http://MarketSourceResearch.com/register/?so=SXI
-----------------------------------------
ABOUT MARKET SOURCE RESEARCH
Market Source Research delivers the key research reports that helps serious investors, registered brokers, professional traders, and personal investment advisers find reliable information in today's markets. Market Source Research's team is comprised of financial professionals, many of which hold Chartered Financial Analyst® (CFA®) designations and FINRA® BrokerCheck® certifications. Whether identifying emerging trends, or discovering new opportunity, the team at Market Source Research is dedicated to providing accurate, informative, and objective content that's ahead of the curve. With insights on individual companies as well as sectors, readers get the industry's best available combination of big-picture perspective as well as granular detail.
REGISTERED MEMBER STATUS
Market Source Research's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments.